Therapy-Related Hematologic and Renal Adverse Events After 225Ac-PSMA-I&T According to Common Terminology Criteria for Adverse Events, Version 5.0
| Event | Before TAT | After TAT | ||||||
|---|---|---|---|---|---|---|---|---|
| Gr. 1 | Gr. 2 | Gr. 3 | Gr. 4 | Gr. 1 | Gr. 2 | Gr. 3 | Gr. 4 | |
| Hematologic | ||||||||
| Anemia | 8 (57%) | 4 (29%) | 2 (14%) | 3 (21%) | 8 (57%) | 3 (21%) | — | |
| Thrombopenia | 3 (21%) | 1 (7%) | — | — | 3 (21%) | 3 (21%) | — | — |
| Leukopenia | 2 (14%) | 1 (7%) | — | — | 4 (28%) | — | 1 (7%) | — |
| Renal | 1 (7%) | — | — | — | 1 (7%) | 1 (7%) | — | — |
| Gastrointestinal | ||||||||
| Xerostomia | 6 (43%) | 2 (14%) | — | ND | 8 (57%) | 5 (36%) | — | ND |
| Dysgeusia | — | — | — | — | 5 (36%) | 1 (7%) | — | — |
| Anorexia | 9 (64%) | — | — | — | 7 (50%) | 2 (14%) | — | — |
| Nausea | — | — | — | — | 4 (29%) | 1 (7%) | — | — |
| General | ||||||||
| Fatigue | 10 (71%) | 1 (7%) | — | — | 6 (43%) | 6 (43%) | — | — |
| Weight loss | NA | NA | NA | NA | 4 (29%) | — | — | — |
Gr. = grade; ND = not defined; NA = not applicable.
Data are number and percentage.